N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
Inventors
Bhamra, Inder • Bingham, Matilda • Testar, Richard • Sargent, Louise • Donoghue, Craig
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
Core Innovation
The disclosure relates to treating a condition mediated by the Wnt signalling pathway by administering to a patient in need thereof a therapeutic amount of a pharmaceutical formulation comprising a compound of formula (III). The condition is selected from cancer, sarcoma, melanoma, skin cancer, hematological tumors, lymphoma, carcinoma, and leukemia. The Wnt inhibition approach is tied to porcupine (Porcn) inhibition, described as Wnt-pathway modulation via porcupine (Porcn) inhibition.
The compounds of formula (III) are defined by structural constraints involving X1 and X2, where one of X1 and X2 is CR6 and the other is N. The structure further includes het2 and het3, each being a 6 membered heteroaryl ring containing 1, 2 or 3 N heteroatoms, which may be unsubstituted or substituted with groups selected from halo, C1-4 alkyl, C1-4 haloalkyl, —OR_A1, —NR_A1R_B1, —CN, and NR_A1C(O)R_B1.
The patent describes synthetic chemistry for intermediates and exemplified final compounds based on General Scheme 2, including substituted heteroaryl acetamides and N-pyridinyl acetamide derivatives as Wnt-pathway inhibitors. The examples include preparation of analogs with variation on pyrazole boronate and aryl halide components, together with additional heteroaryl substituents such as pyridyl and pyrimidyl, and substitution patterns incorporating difluoromethyl, cyano, fluorinated groups, thiazole, and isothiazole ring modifications.
Claims Coverage
The consolidated claim coverage includes two independent therapeutic method claims directed to treating a Wnt signalling pathway-mediated condition by administering a therapeutic amount of a pharmaceutical formulation. Across the items, the core inventive features are the compound of formula (III), the constrained heteroaryl ring framework, the X1/X2 identity requirement, defined substituent groups for R1-R6, parameter limits for m and n, and the use of a pharmaceutically acceptable excipient.
Wnt signalling pathway-mediated treatment with formula (III) compound
A method of treating a condition mediated by the Wnt signalling pathway selected from cancer, sarcoma, melanoma, skin cancer, hematological tumors, lymphoma, carcinoma, and leukemia, comprising administering to a patient a therapeutic amount of a pharmaceutical formulation comprising a compound of formula (III).
Constrained X1 and X2 substitution pattern with CR6 and N
The compound of formula (III) is defined such that X1 and X2 are selected from CR6 and N, provided that one of X1 and X2 is CR6 and the other is N.
Heteroaryl core het2 and het3 with N-containing 6-membered rings
The compound of formula (III) includes het2 and het3, each being a 6 membered heteroaryl ring containing 1, 2 or 3 N heteroatoms, optionally unsubstituted or substituted with groups independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, —OR_A1, —NR_A1R_B1, —CN, and NR_A1C(O)R_B1.
Defined substituent variable restrictions for R1–R6, m and n
The compound of formula (III) further limits R1 and R2 each to H, constrains R3 and R4/R5/R6 to specified substituent sets, sets m as 1, sets n to 0, 1 or 2, and specifies that R_A1, R_B1, R_A2, R_B2, R_A4 and R_B4 are each independently selected from H, C1-4 alkyl, and C1-4 haloalkyl.
Oral administration and narrower het2 selections
The pharmaceutical formulation is administered orally, and het2 is selected from unsubstituted or substituted pyridine, pyrazine, pyrimidine, or pyridazine, with het2 substituted with methyl or trifluoromethyl and n specified as 0.
Overall, the claim coverage centers on administering a therapeutic amount of a pharmaceutical formulation comprising a compound of formula (III) for a Wnt signalling pathway-mediated condition. The coverage is anchored by the X1/X2 CR6/N arrangement, the N-containing 6-membered heteroaryl rings het2 and het3 with a defined substitution set, constrained substituent variables including R1–R6 together with m and n, and a narrower set of oral administration and het2 limitations.
Stated Advantages
Wnt-pathway inhibition.
Targets Porcupine (PORCN).
Modulate Wnt signalling components such as Wnt ligands, frizzled (Fzd), Lrp5/Lrp6, β-catenin, TCF/LEF, and elements of the destruction complex including Axin, APC, GSK-3β, and Dishevelled (Dvl).
Documented Applications
A method of treating conditions mediated by the Wnt signalling pathway, including cancer, sarcoma, melanoma, skin cancer, hematological tumors, lymphoma, carcinoma, and leukemia.
A Dual-Cell β-Catenin reporter assay using Wnt-3a expressing L-Wnt cells and luciferase Wnt reporter cells to assess Wnt pathway inhibition by IC50-based activity categories and selected numeric IC50 values for exemplified compounds.
Interested in licensing this patent?